ICAD iCAD: Earnings per share for the trailing year

Public company logo of iCAD Inc. (ICAD)

Low geopolitical risks and the humanitarian status of AI diagnostics ensure the stability of iCAD, Inc. (ICAD) in the US and Europe. Net income per share YoY ttm growth demonstrates development dynamics, with the indicator recorded at 32.70. The company's strategy is based on implementing deep learning into CT and mammography to combat cancer. Business efficiency relies on the accuracy of algorithms and their integration into radiological systems.

iCAD Inc. (ICAD): Net earnings per share (EPS TTM) from 02/11/2024 to 02/20/2024

iCAD, Inc. - analytical breakdowns and key metrics (ICAD)

- current quotes and average value forecast:
Stock Price iCAD|ICAD - Price Target Chart
- company stock capitalization data:
Market Value iCAD Corp|ICAD - Enterprise Value
- issuer book value statistics:
Net Asset Value per Share iCAD|ICAD - Book Capitalization|Market Capitalization to Book Value icadmed.com|ICAD - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio iCAD, Inc.|ICAD - Long-Term Debt to Capital|Short-Term Debt to Capital icadmed.com|ICAD - Company Aggregate Debts|Debt to Book Value Ratio iCAD|ICAD - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings iCAD|Interim Coverage Ratio icadmed.com
- net income and valuation ratios data:
ICAD - Company Net Income|Net Profit Forecast iCAD, Inc.|ICAD - P/E Multiple|Projected Price to Earnings iCAD Inc.|ICAD - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio iCAD Corp|ICAD - Operating profit EBITDA|Net earnings per share for the last four quarters iCAD|ICAD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months icadmed.com|ICAD - Earnings growth in current year|Earnings growth forecast for next year iCAD, Inc.
- sales and revenue indicators:
ICAD - Revenue and Sales Volume|Company Revenue Forecast icadmed.com|ICAD - P/S Multiple|Forward Price-to-Revenue Multiple iCAD Corp|ICAD - Sales Growth YoY (TTM)
Fundamental company valuation:iCAD, Inc., ICAD
Manufactured product of iCAD Corp

I am assessing the ability of iCAD, Inc. (ICAD) to withstand market volatility through profitability analysis. The scaling of ProFound AI and partnerships with GE and Google must convert into actual cash flow. This chart of YoY ttm earnings per share growth rates measures EPS dynamics over the year, smoothing out the gaps between reports. This allows for the identification of hidden reversal points or the exhaustion of growth potential. This vector confirms the fundamental resilience of the business.

Direct competitors

Earnings per share for the trailing year ONC (BeiGene)|Halozyme Inc. (HALO) - Earnings per share for the last twelve months|RevMed - Earnings per share for the trailing year|AAPG (Ascentage Pharma Group International) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CG Oncology, Inc. CGON|Net earnings per share for the last 12 months URGN (urogen.com)|Earnings per share for the last twelve months BCAX (Bicara Therapeutics)|Net earnings per share (EPS TTM) PSNL (personalis.com)|Earnings per share for the trailing year ERAS|DCTH - Earnings per share for the last twelve months|Y-mAbs Therapeutics (YMAB) - Net earnings per share for the last 12 months|AURA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months CADL|Earnings per share for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months ACTU (Actuate Therapeutics, Inc)|Net earnings per share for the last four quarters Citius Oncology|TuHURA Biosciences, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Protara TARA|fatetherapeutics.com - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aadi Bioscience|TCRX: Net earnings per share (EPS TTM)|CSBR - Net earnings per share for the last four quarters|XBIT (XBiotech) - Net earnings per share (EPS TTM)|CVM: Earnings per share for the trailing year|Net earnings per share (EPS TTM) OSTX|RADX (Radiopharm Theranostics Limited) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ARTV (Artiva Biotherapeutics, Inc.)|Earnings per share for the trailing year ANL|VERU: Net earnings per share for the last 12 months|TPST - Net earnings per share (EPS TTM)|XLO (xiliotx.com) - Net earnings per share for the last 12 months|Renovaro Biosciences - Earnings per share for the trailing year|Net earnings per share for the last 12 months MURA|Earnings per share for the last twelve months KAPA|Net earnings per share for the last 12 months OKUR (OnKure Therapeutics Inc)|Net earnings per share (EPS TTM) CytoMed (GDTC)|Earnings per share for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Earnings per one share for the last 12 months|Tharimmune Corporation - Net earnings per share (EPS TTM)|ADVB (advanbiomed.com) - Earnings per share for the last 12 months|Genprex, Inc (GNPX) - Earnings per share for the last twelve months|CLDI: Earnings per share for the last four quarters|SBFM (Sunshine Biopharma, Inc.) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months XBIO (Xenetic Biosciences)|Net earnings per share (EPS TTM) SLRX|Purple Biotech - Earnings per share for the last 12 months|American Oncology Network - Net earnings per share for the last 12 months|Earnings per share for the trailing year BGNE|CKPT - Earnings per share for the last twelve months|Elevation Oncology (ELEV) - Net earnings per share for the last 12 months|IKNA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NTBL|VIRX (viracta.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months MorphoSys Inc MOR|Earnings per share for the last twelve months NAYA Bio (NAYA)|AAPGV: Earnings per one share for the last 12 months